Archive | 12:28 pm

Dr. Michael Har-Noy Describes The Vaccination Phase Of His CRCL-AlloVaxTM Study Protocol (Part 1)

4 Apr

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., says that the vaccination phase of his CRCL-AlloVaxTM study protocol falls between Days 11 and 21. This vaccination phase is engineered to produce immunity against the patient’s own cancer cells. Dr. Michael Har-Noy says we know that anti-tumor vaccines need a powerful adjuvant effect to create an effective anti-tumor immune response and to imprint this response over the previous one that originally failed to protect the patient against progression of the tumor.

Dr. Michael Har-Noy adds that in order to create this strong adjuvant effect, both the properties of AlloStim™ and the previously primed status of the patient are used. First, AlloStim™ is again administered to the patient by intradermal injection. This repeat AlloStim™ dose precipitates a powerful rejection response led by the type 1 T-helper (Th1) and cytotoxic T-lymphocyte (CTL) memory cells that were created during the previous priming phase of the study protocol. Next, says Dr. Michael Har-Noy, the Chaperone Rich Cell Lysate (CRCL) is injected into this highly inflammatory environment. CRCL contains chaperone proteins that were isolated from the patient’s own tumor cells. These chaperone proteins express many tumor antigens. When the patient’s skin Langerhans cells migrate to clean up the waste products from the rejection of the foreign AlloStim™, they also begin to process the tumor antigens from the CRCL. Dr. Michael Har-Noy says that this tricks the patient’s immune system into believing that the tumor antigens are really part of the recognized foreign antigens in the AlloStim™. Therefore, says Dr. Michael Har-Noy, each exposure of the patient’s immune system to similar tumor antigens and foreign antigens results in the release into the circulation of increased memory Th1 and CTL cells that are specific for these same tumor and foreign antigens.

For more information about Dr. Michael Har-Noy’s phase I/II CRCL-AlloVaxTM study protocol and his Compassionate Use program in Bangkok, Thailand, please visitwww.immunocare.net .

Advertisements